NCT07132333Recruiting
Molecular Inflammation Board at the Center for Personalized Medicine
The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 20 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Molecular Inflammation Board at the Center for Personalized Medicine
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 11 Aug 2025
- Start date
- 16 Nov 2022
- Primary completion date
- Nov 2032
- Lead sponsor
- University Hospital Tuebingen
- Diseases
- Psoriasis, Crohn's disease, Ulcerative colitis
- NCT number
- NCT07132333
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 16 Nov 2022 to the primary completion date, Nov 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No capacity to consent
Who the study is looking for
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Tübingen - Center for Personalized Medicine Coordinator of this site? Confirm its status | Tübingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.